Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Gains from Investment Securities (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Gains from Investment Securities for 6 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 217.17% to -$2.3 million in Q4 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 46.83% decrease, with the full-year FY2024 number at $13.4 million, up 1242.74% from a year prior.
  • Gains from Investment Securities was -$2.3 million for Q4 2025 at GeneDx Holdings, down from $1.2 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $81.7 million in Q3 2021 to a low of -$42.2 million in Q2 2022.
  • A 5-year average of $5.3 million and a median of $871000.0 in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 400.1% in 2021, then crashed 442.71% in 2022.
  • GeneDx Holdings' Gains from Investment Securities stood at $768000.0 in 2021, then plummeted by 442.71% to -$2.6 million in 2022, then fell by 25.49% to -$3.3 million in 2023, then surged by 159.95% to $2.0 million in 2024, then plummeted by 217.17% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Gains from Investment Securities are -$2.3 million (Q4 2025), $1.2 million (Q3 2025), and $551000.0 (Q2 2025).